---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-065618"
form_type: "8-K"
ticker: "RVMD"
cik: "0001628171"
company_name: "Revolution Medicines, Inc."
filed_at: "2025-05-07T23:59:59+00:00"
generated_at: "2026-05-22T08:14:39.863169+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Revolution Medicines Q1 net loss $213.4M; highlights encouraging RAS inhibitor data

## Summary
- Net loss $213.4M (vs $116.0M YoY); R&D $205.7M, G&A $35.0M; cash $2.1B.
- FY 2025 GAAP net loss guidance reaffirmed $840M-$900M; cash runway into H2 2027.
- Daraxonrasib Phase 3 PDAC trial enrollment to substantially complete in 2025; data in 2026.
- Zoldonrasib G12D NSCLC ORR 61%; elironrasib G12C NSCLC ORR 56%, median PFS 9.9 mo.
- Anthony Mancini named chief global commercialization officer.

## SEC filing metadata
- accession: 0000950170-25-065618
- form_type: 8-K
- ticker: RVMD
- cik: 0001628171
- company_name: Revolution Medicines, Inc.
- filed_at: 2025-05-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1628171/000095017025065618/0000950170-25-065618-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1628171/000095017025065618/rvmd-20250507.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-065618
- JSON: https://secwatch.observer/filing/0000950170-25-065618.json
- Plain text: https://secwatch.observer/filing/0000950170-25-065618.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.